Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

90 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH. Palmer AJ, et al. Among authors: roze s. Diabetes Care. 2004 Aug;27(8):1897-903. doi: 10.2337/diacare.27.8.1897. Diabetes Care. 2004. PMID: 15277414
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA. Palmer AJ, et al. Among authors: roze s. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51. doi: 10.1185/030079904X2015. Curr Med Res Opin. 2004. PMID: 15324515
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. Palmer AJ, et al. Among authors: roze s. Curr Med Res Opin. 2004 Aug;20 Suppl 1:S59-66. doi: 10.1185/030079904X2024. Curr Med Res Opin. 2004. PMID: 15324517
90 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page